imipramine has been researched along with Osteoporosis, Postmenopausal in 1 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, L | 1 |
| Peng, Y | 1 |
| Jiang, Y | 1 |
| Wu, Y | 1 |
| Ding, Y | 1 |
| Wang, Y | 1 |
| Xu, D | 1 |
| Fu, Q | 1 |
1 other study available for imipramine and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles.
Topics: Animals; Bone Density Conservation Agents; Cell Differentiation; Cell Line; Cell-Derived Micropartic | 2017 |